Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) have an impaired response to vaccination, which calls for improved vaccination strategies. This study aimed to evaluate antibody persistence 5 years after pneumococcal vaccination and response to revaccination. Seventy-four CLL patients and 31 controls, all primary immunized with 13-valent conjugated pneumococcal vaccine (PCV13) or 23-valent polysac
